Compare CDZI & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CDZI | MNPR |
|---|---|---|
| Founded | 1983 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 444.6M | 421.0M |
| IPO Year | N/A | 2019 |
| Metric | CDZI | MNPR |
|---|---|---|
| Price | $6.68 | $70.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $101.42 |
| AVG Volume (30 Days) | ★ 857.9K | 343.0K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,979,000.00 | N/A |
| Revenue This Year | $58.18 | N/A |
| Revenue Next Year | $32.89 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 188.33 | N/A |
| 52 Week Low | $2.13 | $26.06 |
| 52 Week High | $6.96 | $105.00 |
| Indicator | CDZI | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 61.49 | 54.51 |
| Support Level | $6.21 | $67.33 |
| Resistance Level | $6.96 | $72.75 |
| Average True Range (ATR) | 0.43 | 5.71 |
| MACD | 0.06 | 1.29 |
| Stochastic Oscillator | 78.12 | 92.77 |
Cadiz Inc is a water solutions provider, dedicated to delivering clean, reliable, and affordable water for people. It provides water solutions with a combination of land, water, pipeline, and water filtration assets located in Southern California between key water systems serving population centers in the Southwestern United States. The company operates in two reportable segments; Land and Water Resources segment, which derives key revenue, and comprises all activities regarding its properties in the eastern Mojave Desert, pre-revenue development of the Mojave Groundwater Bank (supply, storage, and conveyance), and agricultural operations; and the Water Filtration Technology segment, which provides water filtration solutions for impaired or contaminated groundwater sources.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.